GTHP's cervical cancer scan is approved in EU, Asia, Canada, Mexico.
Orders from Turkey, Kenya, Bangladesh, China have been received.
Sales are ramping up for a huge untapped market.
EXAS, which has a scan for colorectal cancer with inferior technology, has a market cap exceeding $2 billion .
GTHP's biophotonic scan is non invasive, more accurate than pap smears and produces immediate test results.